glp 1 neurotransmitter Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics Glucagon-Like Peptide-1 and Hypothalamic Regulation

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

The recent research also found that although persistence among the 45 percent of the population using weekly-dosed semaglutide (Ozempic and Wegovy ) was somewhat better, still only 1 in 4 of those initiating semaglutide treatment for obesity remained on GLP-1 therapy at two years

M.HornC

Clinicians should screen for history of pancreatitis, severe gastrointestinal disease (particularly severe gastroparesis), diabetic retinopathy (particularly if intensifying glycemic control rapidly), and gallbladder disease, as these conditions may influence treatment decisions or require closer monitoring